{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:04:28Z","timestamp":1765814668159,"version":"3.48.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:p>\n                    This study retrospectively evaluates and compares the clinical effects of dapagliflozin and linagliptin on cardiac function and glycemic control in patients with type 2 diabetes mellitus (T2DM) complicated by heart failure (HF), thereby providing real-world evidence to support clinical decision-making. This retrospective study included 200 patients with both T2DM and HF, who were divided into 2 groups based on their treatment regimens: a control group and a treatment group (100 patients each). All patients received standard anti-HF therapy in combination with metformin. The control group was administered linagliptin (5\u2009mg once daily before breakfast), while the treatment group received dapagliflozin (10\u2009mg once daily) for a duration of 6 months. Relevant clinical data were collected and analyzed for both groups. Baseline characteristics were comparable between the 2 groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). The total effective rate was significantly higher in the treatment group compared with the control group (97.5% vs 80.0%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), indicating a superior improvement in clinical symptoms with dapagliflozin. Both groups showed significant reductions in fasting blood glucose, 2-hour postprandial blood glucose, and HbA1c compared with baseline values (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), with no statistically significant differences between groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05), suggesting that both drugs effectively improve glycemic control. The treatment group demonstrated greater improvements in NT-proBNP, fibroblast growth factor 23, central pulse pressure, left ventricular ejection fraction, left ventricular end-diastolic diameter, and left ventricular remodeling index compared with the control group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05), indicating a more pronounced effect of dapagliflozin on cardiac function. The incidence of adverse drug reactions was low and not significantly different between groups (2.0% in the control group vs 4.0% in the treatment group,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). Both dapagliflozin and linagliptin effectively improve glycemic control and cardiac function in patients with T2DM and HF, with favorable safety profiles. However, dapagliflozin appears to confer additional benefits in improving cardiac function, potentially due to its unique pharmacological mechanism.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044709","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:44Z","timestamp":1765814444000},"page":"e44709","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of dapagliflozin and linagliptin in managing type 2 diabetes mellitus and heart failure: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"given":"Wenxin","family":"Zai","sequence":"first","affiliation":[{"name":"Department of Cardiovascular, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, Hubei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, Hubei Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, Hubei Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6078-3862","authenticated-orcid":false,"given":"Bo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, Hubei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9149(02)02553-5","article-title":"Insulin resistance as the core defect in type 2 diabetes mellitus.","volume":"90","author":"Goldstein","year":"2002","journal-title":"Am J Cardiol"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus.","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus.","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association.","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies.","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus\u2013mechanisms, management, and clinical considerations.","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-020-01457-6","article-title":"Incidence of heart failure among diabetic patients with ischemic heart disease: a cohort study.","volume":"20","author":"Abdissa","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"52","DOI":"10.15420\/cfr.2016:20:2","article-title":"Heart failure in patients with diabetes mellitus.","volume":"3","author":"Rosano","year":"2017","journal-title":"Card Fail Rev"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide.","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry.","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"1369908","DOI":"10.3389\/fendo.2024.1369908","article-title":"Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.","volume":"15","author":"Deng","year":"2024","journal-title":"Front Endocrinol"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"708547","DOI":"10.3389\/fnins.2021.708547","article-title":"Role of DPP-4 and SGLT2 inhibitors connected to Alzheimer disease in type 2 diabetes mellitus.","volume":"15","author":"Sim","year":"2021","journal-title":"Front Neurosci"},{"key":"R13-20251215","first-page":"35","article-title":"Combination of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase-4 inhibitor: a complementary approach to diabetes management.","volume":"5","author":"Faruqui","year":"2022","journal-title":"Asian J Res Rep Endocrinol"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"725465","DOI":"10.3389\/fonc.2021.725465","article-title":"Sodium-glucose co-transporter 2 inhibitors may change the development of urinary tract and hematological malignancies as compared with dipeptidyl peptidase-4 inhibitors: data of the post-hoc analysis of a nationwide study.","volume":"11","author":"Rokszin","year":"2021","journal-title":"Front Oncol"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect.","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00228-014-1727-5","article-title":"Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.","volume":"70","author":"Grunberger","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-20251215","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neurobiolaging.2020.01.004","article-title":"Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.","volume":"89","author":"Lietzau","year":"2020","journal-title":"Neurobiol Aging"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"e0187537","DOI":"10.1371\/journal.pone.0187537","article-title":"The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.","volume":"12","author":"Yang","year":"2017","journal-title":"PLoS One"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"H477","DOI":"10.1152\/ajpheart.00209.2014","article-title":"Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.","volume":"307","author":"Aroor","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R21-20251215","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/1932296818775755","article-title":"Use of blood glucose meters featuring color range indicators improves glycemic control in patients with diabetes in comparison to blood glucose meters without color (ACCENTS Study).","volume":"12","author":"Grady","year":"2018","journal-title":"J Diabetes Sci Technol"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"672348","DOI":"10.3389\/fmed.2021.672348","article-title":"Propensity for calcification in serum associates with 2-year cardiovascular mortality in ischemic heart failure with reduced ejection fraction.","volume":"8","author":"Bojic","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ejrad.2015.04.026","article-title":"Left ventricular remodeling and fibrosis: sex differences and relationship with diastolic function in hypertrophic cardiomyopathy.","volume":"84","author":"Chen","year":"2015","journal-title":"Eur J Radiol"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/ehf2.14529","article-title":"The potential predictive value of cardiac mechanics for left ventricular reverse remodelling in dilated cardiomyopathy.","volume":"10","author":"Kan","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"2_suppl","key":"R27-20251215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications.","volume":"26","author":"Dal Canto","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"R28-20251215","first-page":"e45835","article-title":"Cardiovascular complications of diabetes: from microvascular to macrovascular pathways.","volume":"15","author":"Zakir","year":"2023","journal-title":"Cureus"},{"key":"R29-20251215","doi-asserted-by":"crossref","first-page":"E1163","DOI":"10.1210\/jc.2013-1029","article-title":"The DPP-4 inhibitor linagliptin restores \u03b2-cell function and survival in human isolated islets through GLP-1 stabilization.","volume":"98","author":"Shah","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-20251215","doi-asserted-by":"crossref","first-page":"464622","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors.","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front Endocrinol"},{"key":"R31-20251215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/DMSO.S22503","article-title":"Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.","volume":"5","author":"Whaley","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R32-20251215","first-page":"10","article-title":"Study the association of asprosin and dickkopf-3 with KIM-1, NTpro-BNP, GDF-15 and CPP among male iraqi with chronic kidney disease.","volume":"11","author":"Alaaraji","year":"2020","journal-title":"Syst Rev Pharm"},{"key":"R33-20251215","doi-asserted-by":"crossref","first-page":"154123","DOI":"10.1016\/j.jcrc.2022.154123","article-title":"NT-proBNP and troponin I in high-grade aneurysmal subarachnoid hemorrhage: relation to clinical course and outcome.","volume":"72","author":"Svedung Wettervik","year":"2022","journal-title":"J Crit Care"},{"key":"R34-20251215","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/CIA.S68193","article-title":"Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged\u2265 65 years) with type 2 diabetes.","volume":"9","author":"Iqbal","year":"2014","journal-title":"Clin Interv Aging"},{"key":"R35-20251215","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.","volume":"147","author":"Bolen","year":"2007","journal-title":"Ann Intern Med"},{"key":"R36-20251215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14740338.2016.1246531","article-title":"Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013\u20132016) analysis.","volume":"15","author":"Leporini","year":"2016","journal-title":"Expert Opin Drug Saf"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:49Z","timestamp":1765814449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":33,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044709","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2024-10-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}